BioSpace News Archive

Additionally, Announces Accretive Acquisition of ActivStyle, a Home Medical Supply Provider

Beacon Targeted Therapies, a Hanson Wade Ltd company, is a leader in bespoke and tailored clinical trial and drug development database products in targeted therapies providing accurate, in-depth, and real-time information on the rapidly evolving drug development landscapes.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.

Tissue from presymptomatic patient in Italy was found to contain SARS-CoV-2 using Company’s Logix Smart™ COVID-19 test kit

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that management will participate in the Jefferies 2020 Virtual Healthcare Conference being held from June 2-4, 2020.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today’s announcements are: Merck to acquire Themis Bioscience, a company focused on vaccines and immune-modulati

Sensor Electronic Technology, Inc. (“SETi”), the World’s first compound semiconductor for UV LED solutions (Violeds) and Seoul Viosys (KOSDAQ: 092190)’ subsidiary, announced that it launches portable air purifiers with Violeds technology, brand “VAC”, to reduce infection from various harmful bacteria including new coronavirus (SARS-CoV-2) in the air. The online sales of the products will be started in both South Korea and

Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2

Caladrius Biosciences, Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,084,850 shares of its common stock, at a purchase price of $2.0625 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

Allena Pharmaceuticals, Inc. announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 2:30 p.m.